Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-052190
Filing Date
2020-11-09
Accepted
2020-11-09 07:31:00
Documents
69
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cmpx-10q_20200930.htm 10-Q 2345266
2 EX-31.1 cmpx-ex311_6.htm EX-31.1 18532
3 EX-31.2 cmpx-ex312_8.htm EX-31.2 18606
4 EX-32.1 cmpx-ex321_9.htm EX-32.1 9187
5 EX-32.2 cmpx-ex322_7.htm EX-32.2 9093
  Complete submission text file 0001564590-20-052190.txt   7210635

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT cmpx-20200930.xml EX-101.INS 1402843
7 XBRL TAXONOMY EXTENSION SCHEMA cmpx-20200930.xsd EX-101.SCH 48701
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cmpx-20200930_cal.xml EX-101.CAL 40358
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmpx-20200930_def.xml EX-101.DEF 179869
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmpx-20200930_lab.xml EX-101.LAB 384423
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmpx-20200930_pre.xml EX-101.PRE 317547
Mailing Address 245 FIRST STREET, 3RD FLOOR CAMBRIDGE MA 02142
Business Address 245 FIRST STREET, 3RD FLOOR CAMBRIDGE MA 02142 617-500-8099
Compass Therapeutics, Inc. (Filer) CIK: 0001738021 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55939 | Film No.: 201296096
SIC: 2836 Biological Products, (No Diagnostic Substances)